

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The bispecific antibody zanidatamab binds to which of the following?**
  - a. Two distinct HER2 domains**
  - HER2 and CD38
  - CD8 and CLDN18.2
  - HER2 and FGFR2b
- 2. Which of the following statements best represents observations with pembrolizumab when added to chemotherapy for patients with advanced biliary tract cancer in the Phase III KEYNOTE-966 trial?**
  - Objective response rate was significantly improved with pembrolizumab
  - b. Overall survival was significantly improved with pembrolizumab**
  - Both a and b
  - Neither a nor b
- 3. Which of the following toxicities was most commonly observed in patients receiving ivosidenib for advanced cholangiocarcinoma with an IDH1 mutation in the Phase III ClarIDHy trial?**
  - a. Gastrointestinal**
  - Ocular
  - Neurologic
  - Dermatologic
- 4. Which of the following adverse events was most commonly observed in patients receiving zanidatamab for previously treated HER2-amplified biliary tract cancer in the HERIZON-BTC-01 study?**
  - Headache
  - Blurred vision
  - Dry mouth
  - d. Diarrhea**
- 5. Which of the following statements best describes the frequency of any-grade adverse events (AEs) with durvalumab/tremelimumab versus sorafenib in the Phase III HIMALAYA trial?**
  - AEs were significantly decreased with durvalumab/tremelimumab
  - AEs were significantly increased with durvalumab/tremelimumab
  - c. AEs were similar with durvalumab/tremelimumab and sorafenib**